ContactISSN:e-ISSN: 2757-976X
Author Sign-inReviewer Sign-inRegister
TürkçeEnglish
Home
About Journal
Copyright NoticeOpen Access PolicyAim and ScopePrinciples of ArbitrationReviewer and Editor GuideFee PolicyEthical Principles and Publication PolicyArchiving PolicyIndexing
Information For AuthorsEditorial BoardSend ArticleLatest IssueArchiveContact Us

THE ROLE OF OREXIN IN THE PHYSIOPATHOLOGY OF NEUROPSYCHIATRIC DISEASES

RAVİYE ÖZEN KOCA,Z IŞIK SOLAK GÖRMÜŞ,Şükrü Ekenler,Berat Yıldırım,Merve Akalın,Büşra Simsar

  • RAVİYE ÖZEN KOCA: NECMETTİN ERBAKAN ÜNİVERSİTESİ
  • Z IŞIK SOLAK GÖRMÜŞ: NECMETTİN ERBAKAN ÜNİVERSİTESİ
  • Şükrü Ekenler: NECMETTİN ERBAKAN ÜNİVERSİTESİ
  • Berat Yıldırım: NECMETTİN ERBAKAN ÜNİVERSİTESİ
  • Merve Akalın: NECMETTİN ERBAKAN ÜNİVERSİTESİ
  • Büşra Simsar: NECMETTİN ERBAKAN ÜNİVERSİTESİ
  •  Year : 2025
  •  Vol : 5
  •  Issue : 1
  •  Page : 22-29
Orexins (hypocretins) have attracted the attention of the scientific community in different pathological mechanisms since their discovery in 1998. Orexin peptides consist of two types, orexin A and B, encoded by the hypocretin neuropeptide precursor gene and then produced from the same precursor, prepro-orexin. Orexin-producing neurones are located in the lateral, dorsomedial, posterior and perifornical regions of the hypothalamus. Orexin A and B signalling is mediated by two G protein-coupled receptors called orexin1 and orexin2 receptors. The signalling of orexin peptides has been investigated in various cells, such as neurons endogenously expressing orexin receptors. The orexin1 receptor is found mainly in regions controlling feeding, learning, memory and reward, whereas the orexin2 receptor is found mainly in regions controlling arousal. From the distribution of orexin neurons and receptors, the orexin system is thought to have multiple functions in physiological mechanisms. Recent evidence suggests that the central orexin system has an important regulatory role for the regulation of food intake and sleep in animal and human models. In addition to its activity in feeding behaviour, orexin also has an active role in energy regulation. Orexin, a hypothalamic neuropeptide that is active in maintaining wakefulness, plays an important role in the regulation of the sleep-wake cycle. Experimental studies with human and animal models in which the effects of orexin system can be analysed in detail may guide therapeutic approaches related to orexin. In this review, the role of orexin in the physiopathological mechanisms of neuropsychiatric disorders such as eating disorders, sleep disorders, addiction, schizophrenia, epilepsy, depression and anxiety is explained.
Cite this Article As : Özen Koca R, Solak Görmüş ZI, Ekenler Ş, Yıldırım B, Akalın M, Simsar B. Nöropsikiyatrik Hastalıkların Fizyopatolojisinde Oreksin’in Rolü. Mev Med Sci. 2025; 5(1): 22-29

Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.
Mevlana Tıp Bilimleri
2025, Vol5, Issue1
E-ISSN: 2757-976X
Received : , Accepted : , Published Online :

References

  1. 1. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 998;92(4):573-85.
  2. 2. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95(1):322-7.
  3. 3. Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50.
  4. 4. Soya S, Sakurai T. Evolution of Orexin Neuropeptide System: Structure and Function. Front Neurosci 2020;14:691.
  5. 5. Xia L, Liu HY, Wang BY, et al. A review of physiological functions of orexin: From instinctive responses to subjective cognition. Medicine (Baltimore) 2023;102(26):e34206.
  6. 6. Bigalke JA, Shan Z, Carter JR. Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function. Hypertension 2022;79(12):2643-55.
  7. 7. Al Massadi O, López M, Tschöp M, et al. Current Understanding of the Hypothalamic Ghrelin Pathways Inducing Appetite and Adiposity. Trends in Neurosciences 2017;40(3):167-80.
  8. 8. Wang Z, Wu H, Stone WS, et al. Body weight and basal metabolic rate in childhood narcolepsy: a longitudinal study. Sleep Medicine 2016;25:139-44.
  9. 9. Adeghate E, Lotfy M, D’Souza C, et al. Hypocretin/orexin modulates body weight and the metabolism of glucose and insulin. Diabetes Metabolism Res 2020;36(3):e3229.
  10. 10. Maruyama T, Ueta Y. Internal and external modulation factors of the orexin system (REVIEW). Peptides 2023;165:171009.
  11. 11. Mehr JB, Mitchison D, Bowrey HE, et al. Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 2021;46(12):2051-61.
  12. 12. Pankevich DE, Teegarden SL, Hedin AD, et al. Caloric restriction experience reprograms stress and orexigenic pathways and promotes binge eating. J Neurosci 2010;30(48):16399-407.
  13. 13. Brown RM, Dayas CV, James MH, et al. New directions in modelling dysregulated reward seeking for food and drugs. Neurosci Biobehav Rev 2022;132:1037-48.
  14. 14. Enriori PJ, Evans AE, Sinnayah P, et al. Diet-Induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate Melanocortin Neurons. Cell Metabolism 2007;5(3):181-94.
  15. 15. Shin SK, Song SE, Oh JU, et al. Orexin A-induced inhibition of leptin expression and secretion in adipocytes reducing plasma leptin levels and hypothalamic leptin resistance. Pflugers Arch - Eur J Physiol 2019;471(11-12):1407-18.
  16. 16. Świtońska MM, Kaczmarek P, Malendowicz LK, et al. Orexins and adipoinsular axis function in the rat. Regulatory Peptides 2002;104(1-3):69-73.
  17. 17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. American Psychiatric Association 2013.
  18. 18. O’Hara CB, Campbell IC, Schmidt U. A reward-centred model of anorexia nervosa: A focussed narrative review of the neurological and psychophysiological literature. Neurosci BiobehavRev 2015;52:131-52.
  19. 19. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005;437(7058):556-9.
  20. 20. Herrera CG, Ponomarenko A, Korotkova T, et al. Sleep & metabolism: The multitasking ability of lateral hypothalamic inhibitory circuitries. Front Neuroendocrinol 2017;44:27-34.
  21. 21. Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 25 Kasım 2016;354(6315):1004-8.
  22. 22. Seow LSE, Verma SK, Mok YM, et al. Evaluating DSM-5 Insomnia Disorder and the Treatment of Sleep Problems in a Psychiatric Population. J Clin Sleep Med 2018;14(2):237-44.
  23. 23. Rosenberg RP, Benca R, Doghramji P, et al. A 2023 Update on Managing Insomnia in Primary Care: Insights From an Expert Consensus Group. Prim Care Companion CNS Disord 2023.
  24. 24. Morin CM, Vézina-Im LA, Ivers H, et al. Prevalent, incident, and persistent insomnia in a population-based cohort tested before (2018) and during the first-wave of COVID-19 pandemic (2020). Sleep 2022;45(1):zsab258.
  25. 25. Roach M, Juday T, Tuly R, et al. Challenges and opportunities in insomnia disorder. Int J Neurosci 2021;131(11):1058-65.
  26. 26. De Luca R, Nardone S, Grace KP, et al. Orexin neurons inhibit sleep to promote arousal. Nat Commun 2022;13(1):4163.
  27. 27. Shaha DP. Insomnia Management: A Review and Update. J Fam Pract 2023;72(6 Suppl):S31-6.
  28. 28. Yanagisawa M. Toward the Mysteries of Sleep. Keio J Med 2019;68(1):27-27.
  29. 29. Scammell TE. Narcolepsy. Ed: Campion EW. N Engl J Med 2015;373(27):2654-62.
  30. 30. Sheibani M, Shayan M, Khalilzadeh M, et al. Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy. Neuropeptides 2023;99:102335.
  31. 31. Evans R, Kimura H, Alexander R, et al. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc Natl Acad Sci USA 2022;119(35):e2207531119.
  32. 32. Hung C, Yamanaka A. The role of orexin neuron activity in sleep/wakefulness regulation. Peptides 2023;165:171007.
  33. 33. Mohammadi I, Sadeghi M, Tajmiri G, et al. Evaluation of Blood Levels of Omentin-1 and Orexin-A in Adults with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Life (Basel) 2023;13(1):245.
  34. 34. Koob GF, Le Moal M. Addiction and the Brain Antireward System. Annu Rev Psychol 2008;59(1):29-53.
  35. 35. Sharf R, Sarhan M, Dileone RJ. Role of orexin/hypocretin in dependence and addiction. Brain Res 2010;1314:130-8.
  36. 36. Mehr JB, Bilotti MM, James MH. Orexin (hypocretin) and addiction. Trends in Neurosciences 2021;44(11):852-5.
  37. 37. James MH, Mahler SV, Moorman DE, et al. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Ed: Lawrence AJ, de Lecea L. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing 2017; 247-81. (
  38. 38. James MH, Stopper CM, Zimmer BA, et al. Increased Number and Activity of a Lateral Subpopulation of Hypothalamic Orexin/Hypocretin Neurons Underlies the Expression of an Addicted State in Rats. Biol Psychiatry 2019;85(11):925-35.
  39. 39. Bartra Alegría AF, Guerra Sánchez EF, Carranza Esteban RF. Autoconcepto y depresión en estudiantes universitarios de una universidad privada 2019.
  40. 40. Ormel J, Kessler RC, Schoevers R. Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Curr Opin Psychiatry 2019;32(4):348-54.
  41. 41. Fried EI, Nesse RM. Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. J Affect Disord 2015;172:96-102.
  42. 42. Vindas MA, Helland-Riise SH, Nilsson GE, et al. Depression-like state behavioural outputs may confer beneficial outcomes in risky environments. Scientific reports 2019;9(1):3792.
  43. 43. Moncrieff J, Cooper RE, Stockmann T, et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 2023;28(8):3243-56.
  44. 44. Akça ÖF, Uzun N, Kılınç İ. Orexin A in adolescents with anxiety disorders. Int J Psychiatry Clin Pract 2020;24(2):127-34.
  45. 45. Han Y, Yuan K, Zheng Y, et al. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36(4):432-48.
  46. 46. Brooks S, Jacobs GE, De Boer P, et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol 2019;33(2):202-9.
  47. 47. Summers CH, Yaeger JDW, Staton CD, et al. Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy. Brain Res 2020;1731:146085.
  48. 48. Yaeger JDW, Krupp KT, Jacobs BM, et al. Orexin 1 Receptor Antagonism in the Basolateral Amygdala Shifts the Balance From Pro- to Antistress Signaling and Behavior. Biol Psychiatry 2022;91(9):841-52.
  49. 49. Li SB, Nevárez N, Giardino WJ, et al. Optical probing of orexin/hypocretin receptor antagonists. Sleep 2018 Oct 1;41(10):zsy141.
  50. 50. Johnson PL, Federici LM, Fitz SD, et al. Orexın 1 and 2 Receptor Involvement In Co 2 -Induced Panic-Associated Behavior and Autonomıc Responses: Research Article: Orexin Receptor Involvement in CO 2 -Induced Panic. Depress Anxiety 2015;32(9):671-83.
  51. 51. Nakamura M, Nagamine T. Neuroendocrine, Autonomic, and Metabolic Responses to an Orexin Antagonist, Suvorexant, in Psychiatric Patients with Insomnia. Innov Clin Neurosci 2017;14(3-4):30-7.
  52. 52. Petrous J, Furmaga K. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts. BMJ Case Reports 2017;bcr-2017-222037.
  53. 53. Arendt DH, Hassell J, Li H, et al. Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdala. Psychoneuroendocrinology 2014;40:17-26.
  54. 54. Staton CD, Yaeger JDW, Khalid D, et al. Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression. Neuropharmacology 2018;143:79-94.
  55. 55. Wang D, Li A, Dong K, et al. Lateral hypothalamus orexinergic inputs to lateral habenula modulate maladaptation after social defeat stress. Neurobiol Stress 2021;14:100298.
  56. 56. Ziemichód W, Kurowska A, Grabowska K, et al. Characteristics of Seltorexant—Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety. Molecules 2023;28(8):3575.
  57. 57. Karagülleoğlu ZY, Çarhan A. Tarihteki İlk İzleri ile Şizofreni. Lokman Hekim J 2021;11(3):400-10.
  58. 58. Li S, Zhang R, Hu S, et al. Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis. Front Psychiatry 2022;13:879414.
  59. 59. Maness EB, Blumenthal SA, Burk JA. Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia. Behavioural Brain Res 2023;450:114497.
  60. 60. Lambe EK, Liu RJ, Aghajanian GK. Schizophrenia, Hypocretin (Orexin), and the Thalamocortical Activating System. Schizophr Bull 2007;33(6):1284-90.
  61. 61. Al-Kuraishy HM, Abdulhadi MH, Hussien NR, et al. Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review. Brain Circ 2020;6(2):70-80.
  62. 62. Nishino S, Ripley B, Mignot E, et al. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res 2002;110(1):1-7.
  63. 63. Deutch AY, Bubser M. The Orexins/Hypocretins and Schizophrenia. Schizophr Bull 2007;33(6):1277-83.
  64. 64. Chen PY, Chen CH, Chang CK, et al. Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. Int J Neuropsychopharmacol 2018;22(1):28-36.
  65. 65. Hocaoğlu C, Taşkın Uyan T, Köroğlu A. Şizofreni: Etiyoloji, tanı ve tedavi yaklaşımlarında güncel durum. ERÜ Sağlık Bilimleri Fakültesi Dergisi 2023;10(1):19-35.
  66. 66. Li J, Wang Q, Qian J, et al. Correlation of serum Orexin-A level with cognitive function and serum inflammatory cytokines in epileptic patients. Am J Transl Res 2023;15(6):4110-7.
  67. 67. Perucca P, Bahlo M, Berkovic SF. The Genetics of Epilepsy. Annu Rev Genom Hum Genet 2020;21(1):205-30.
  68. 68. Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1333-48.
  69. 69. Henning O, Heuser K, Larsen VS, et al. Temporal lobe epilepsy. T Tidsskr Nor Laegeforen. 2023 Jan 30;143(2).
  70. 70. Elahdadi Salmani M, Sarfi M, Goudarzi I. Chapter Thirteen - Hippocampal orexin receptors: Localization and function. Ed: Litwack G. Vitamins and Hormones, Academic Press. 2022;393-421.
  71. 71. Sheibani M, Shayan M, Khalilzadeh M, et al. Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy. Neuropeptides 2023;99:102335.
  72. 72. Ng MC. Orexin and Epilepsy: Potential Role of REM Sleep. Sleep 2017;40(3):zsw061.
  73. 73. He Z, Wang X, Ma K, et al. Selective activation of the hypothalamic orexinergic but not melanin-concentrating hormone neurons following pilocarpine-induced seizures in rats. Front Neurosci 2022;16:1056706.
  74. 74. Li J, Wang Q, Qian J, et al. Correlation of serum Orexin-A level with cognitive function and serum inflammatory cytokines in epileptic patients. Am J Transl Res 2023;15(6):4110-7.